New Delhi, Nov. 9 -- India's pharmaceutical industry is increasingly shifting towards high-value medicines, complex chemistry and advanced therapies, with manufacturers investing in domestic production of active pharmaceutical ingredients (APIs) to reduce import dependence and strengthen global competitiveness, industry executives said.

Pharma Industry Shifts Towards Innovation-Led Manufacturing

Ahead of CPHI India and PMEC India 2026, industry representatives stressed the need for investment in advanced manufacturing, R&D and proprietary chemical platforms to strengthen domestic capabilities.

Deepak Jain, CEO and Managing Director, Jubilant Ingrevia, said the industry was shifting towards innovation-led and sustainable manufacturing a...